ARCHIVES

Genentech Reps Not Welcome: Hospitals Urge Drug Maker to Reverse Policy On Supplying Avastin, Rituxan, & Herceptin

This article is from The Cancer Letter archive.

Vol. 40 No. 39 | October 17, 2014

Download PDF Visit The Full Archive

Related Articles

Adding Aresenic To Therapy Improves APL Survival

July 27, 2007

Seven New Initiatives For NIH Common Fund

February 26, 2010

Caution Advised for Hormone Replacement Therapy

March 21, 1986

World Conference To Consider Smoking Problem, Research, Action

March 14, 1975

Murphy Puts RPMI On Record

July 22, 1977

NIH Investigation Clear Gallo Of Charge He Stole Aids Virus

October 12, 1990